Patents by Inventor John R. Bial

John R. Bial has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11793178
    Abstract: Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: October 24, 2023
    Assignee: Yecuris Corporation
    Inventors: John R. Bial, Elizabeth M. Wilson, Aron M. Geurts
  • Publication number: 20200008406
    Abstract: Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.
    Type: Application
    Filed: August 30, 2019
    Publication date: January 9, 2020
    Inventors: John R. Bial, Elizabeth M. Wilson, Aron M. Geurts
  • Patent number: 10470445
    Abstract: Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 12, 2019
    Assignee: Yecuris Corporation
    Inventors: John R. Bial, Elizabeth M. Wilson, Aron M. Geurts
  • Publication number: 20160249591
    Abstract: Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 1, 2016
    Inventors: John R. Bial, Elizabeth M. Wilson, Aron M. Geurts
  • Publication number: 20140373187
    Abstract: Described herein are rats with a hepatic deficiency comprising decreased function, activity, or expression of an enzyme in the tyrosine catabolic pathway (such as fumarylacetoacetate hydrolase), and methods of using the same for in vivo engraftment and expansion of heterologous hepatocytes, such as human hepatocytes, analysis of human liver disease, and analysis of xenobiotics. Also disclosed is the use of immunodeficient rats for the engraftment and expansion of heterologous hepatocytes.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 18, 2014
    Applicant: Yecuris Corporation
    Inventors: John R. Bial, Elizabeth M. Wilson, Aron M. Geurts